anti-mesothelin/anti-CD3 bispecific T-cell engager XmAb (Xencor)

N/A

Report date: 2026/03/19 16:58:15

Base Information

Drug Nameanti-mesothelin/anti-CD3 bispecific T-cell engager XmAb (Xencor)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers

Mechanisms of ActionMesothelin modulatorsT cell surface glycoprotein CD3 modulators

TargetsMesothelinT cell surface glycoprotein CD3

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesXencor Inc

Active IndicationsN/A

Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A